Verona Pharma plc – American Depositary Share’s (VRNA) “Outperform” Rating Reiterated at Wedbush
Verona Pharma plc – American Depositary Share (NASDAQ:VRNA)‘s stock had its “outperform” rating restated by equities research analysts at Wedbush in a report issued on Tuesday. They currently have a $33.00 price target on the stock. Wedbush’s price objective suggests a potential upside of 178.48% from the company’s previous close.
Separately, Zacks Investment Research downgraded shares of Verona Pharma plc – American Depositary Share from a “hold” rating to a “sell” rating in a report on Friday, November 10th. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $24.20.
Verona Pharma plc – American Depositary Share (NASDAQ:VRNA) traded up $0.16 during trading hours on Tuesday, hitting $11.85. 7,400 shares of the company’s stock traded hands, compared to its average volume of 4,853. Verona Pharma plc – American Depositary Share has a 12-month low of $10.44 and a 12-month high of $17.50.
Verona Pharma plc – American Depositary Share Company Profile
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companys lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.
Receive News & Ratings for Verona Pharma plc - American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma plc - American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.